Nortriptyline ‘good candidate’ for frontline neuropathic corneal pain treatment

SAN FRANCISCO — The tricyclic antidepressant nortriptyline was “relatively safe” and significantly improved symptoms of neuropathic corneal pain, according to researchers at the American Academy of Ophthalmology annual meeting.
The findings suggested that nortriptyline is a “good candidate to be a first-line treatment” for neuropathic corneal pain with a centralized component, Mehmet C. Ozmen, MD, FICO, postdoctoral clinical research fellow at Tufts Medical Center, Tufts University School of Medicine, and associate professor of ophthalmology at Gazi University

Full Story →